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Background
Pembrolizumab blocks the interaction between PD-1 and
its ligands PD-L1 and PD-L2, thereby inducing an antitu-
mor immune response. In a phase I study, pembrolizu-
mab demonstrated promising antitumor activity and
acceptable safety in patients with ipilimumab-treated
melanoma, leading to accelerated approval in the US.
Materials and methods
KEYNOTE-002 is a randomized phase 2 study in patients
with ipilimumab-refractory melanoma (ie, confirmed PD
in the 24 weeks following ≥2 ipilimumab doses) and, if
BRAF mutant, previously treated with a BRAF inhibitor.
Patients were randomized 1:1:1 to pembrolizumab 2 or
10 mg/kg Q3W or investigator-choice chemotherapy
(carboplatin + paclitaxel, carboplatin, paclitaxel, dacarba-
zine, or temozolomide). Patients with PD confirmed by
independent central review could cross over to pembroli-
zumab treatment after the first 3-month assessment.
Primary objective of the interim analysis prespecified to
occur after ≥ 270 PFS events (RECIST v1.1, independent
central review) was to evaluate the superiority of either
pembrolizumab dose over control for PFS at a 1-sided
0.25% significance level (estimated HR 0.66).
Results
From Nov 2012 to Nov 2013, 540 patients from 12 coun-
tries enrolled. Based on central review of a total of 410
PFS events, the HR was 0.57 and 0.50 for pembrolizumab
2 and 10 mg/kg Q3W, respectively, over control
(P<0.00001 for both comparisons). The 6-month PFS
rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%-
45%) for pembrolizumab 2 and 10 mg/kg, respectively,
compared with 16% (95% CI 10%-22%) for the control
arm. PFS by investigator assessment was similar to that
of central review. The PFS effect was consistent in all
subgroups. ORR was 21% at 2 mg/kg, 25% at 10 mg/kg,
and 4% in the control arm (P<0.0001 for both compari-
sons). Median response duration was not reached in
either pembrolizumab arm and was 37 weeks in the con-
trol arm. Forty-eight percent of patients in the control
arm crossed over to pembrolizumab treatment. OS data
are not mature (final OS analysis will be performed after
370 deaths have occurred). The safety profile was consis-
tent with that previously observed for pembrolizumab.
Despite a decreased therapy duration, rates of grade 3-5
drug-related AEs were numerically higher in the che-
motherapy control arm (26%) than in the pembrolizumab
2-mg/kg (11%) and 10-mg/kg (14%) arms.
Conclusion
Both pembrolizumab doses met prespecified criteria for
PFS superiority over the chemotherapy control arm.
Pembrolizumab significantly prolongs PFS compared
with chemotherapy, approximately doubling the
6-month rate in an ipilimumab-refractory population.
Clinical Trial Registration Number
NCT01704287.
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